Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 720Neoplasms 458Prostatic Neoplasms 397Carcinoma, Non-Small-Cell Lung 387Lung Neoplasms 308Leukemia, Myeloid, Acute 300Multiple Myeloma 269Colorectal Neoplasms 242Neoplasm Metastasis 240Pancreatic Neoplasms 236Leukemia 235Melanoma 214Lymphoma 213Precursor Cell Lymphoblastic Leukemia-Lymphoma 204Brain Neoplasms 193Recurrence 178Head and Neck Neoplasms 177Lymphoma, Non-Hodgkin 173Leukemia, Lymphocytic, Chronic, B-Cell 168Myelodysplastic Syndromes 166Ovarian Neoplasms 160Carcinoma, Hepatocellular 154Glioblastoma 149Carcinoma, Renal Cell 137Rectal Neoplasms 134Colonic Neoplasms 129Lymphoma, Large B-Cell, Diffuse 125Lymphoma, Follicular 125Hodgkin Disease 115Squamous Cell Carcinoma of Head and Neck 109

Interventions

prednylidene 1deltacortene 1cabazitaxel 1XRP6258 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × OTHER × Hormone-Resistant Prostate Cancer × Clear all
NCT02844582 2021-01-25

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of California, Davis

Phase 2 Terminated
2 enrolled 5 charts
Genitourinary

Hormone-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡